Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer.
10.3904/kjim.2013.28.5.525
- Author:
Il Ju CHOI
1
Author Information
1. Center for Gastric Cancer, National Cancer Center, Goyang, Korea. cij1224@ncc.re.kr
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
Stomach neoplasms;
Helicobacter pylori;
Prevention and control
- MeSH:
Anti-Bacterial Agents/*therapeutic use;
Drug Therapy, Combination;
Early Detection of Cancer;
Evidence-Based Medicine;
Gastrectomy;
Gastritis/diagnosis/*drug therapy/microbiology;
Helicobacter Infections/complications/diagnosis/*drug therapy/microbiology;
Humans;
Neoplasm Recurrence, Local;
Practice Guidelines as Topic;
Proton Pump Inhibitors/*therapeutic use;
Risk Factors;
Stomach Neoplasms/diagnosis/microbiology/*prevention & control/surgery;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2013;28(5):525-537
- CountryRepublic of Korea
- Language:English
-
Abstract:
Gastric cancer is the second most common cause of cancer death worldwide and is usually detected at a late stage, except in Korea and Japan where early screening is in effect. Results from animal and epidemiological studies suggest that Helicobacter pylori infection, and subsequent gastritis, promote development of gastric cancer in the infected mucosa. Relatively effective treatment regimens are available to treat H. pylori infection, and in general, mass eradication of the organism is not currently recommended as a gastric cancer prevention strategy. However, regional guidelines vary regarding the indications and recommendations for H. pylori treatment for gastric cancer prevention. In this review, we discuss the results from intervention studies, provide insight regarding current guideline recommendations, and discuss future study directions.
